I have watched Onc since 1999 when they went public.
held shares on & off over thst time.
obviously watching closer when owning shares.
The last 4 years have been quite progressive.
im speaking from a scientific point. The S.P. Obviously like an amusement park roller coaster ride.
They still have pending announcement regarding the PanCan phase 3 invite.
Also further updates on Goblet along side Roche.
Mbc phase 3 fast track approval etc etc etc.
What about the recent " bought deal"?
Strength or weakness?
One positive, they won't be needing the ATM $$$ for 12 months ++. So any future price runs will not be dragged down, by Oncy selling into the market.
Essentially the bought deal, has created a price floor.
im not happy with the 20% haurcut in price. However in that regard.
Some have been going on for yrs , lack of institutional support. Well they certainly have that.
With the warrants attatched , not any logic for the SP to be shorted, like it was last bought deal ( 2018) there abouts on the date.
The Canadian only deal, is very interesting. No idea why. Perhaps to stop shorting?
Strength or weakness?
back in the day. Some may recall the investor relations guy. Michael Moore.
I was on first name basis with him, both telephone & email.
We never met in person, but did grow up in the same town.
His comments regarding ATM & bought deals , cash on hand & negotiations with pharma. ( 2019).
To remain listed, they must have cash on hand to fund a minimum of 12 months of sustainable predictable operations.
onc/ Oncy has zero debt.
The last update shown on ONCs web investor presentation said cash rate 12+ months.( June).
Meaning they probably did not " need" to do the bought deal.
So why?
Back to M.M. Comments to me.
The more $$ on hand Onc has, the stronger their negotiating position.
Afterall, in a buyout, that cash would belong to the new owners.
and they can not use the $$ shortage as leverage.
partnership?
imho Roche is the most likely. They howver need data, to bring to their BOD to justify any $$$ outlays.
That data " goblet" is scheduled for October.
Probably after the 90 day window that Onc stated. " more details" on PanCan invite.
There are so many unknowns right now, I could fill pages of possible outcomes.
I do know the Q2 update in due within 10 days, based on historical updates.
There will be minimum one N.R. Announcing that.
Once the bought deal closes. Tomorrow.
Additional updates would be welcome.
Bad mangement ? Good mangement?
Their only mandate is to get Pela to market as a cancer treatment.
They are now within a few months of hopefully blockbuster results from Goblet.
The initial pancreatic results were just that. Hence the very fast invite from PanCan.
This story will only be over when it's over.
Phase 3 on their own? If successful amazing corporate value.
An extremely complicated puzzle, with many moving parts.
I do know 100% for sure. They are well guided with existing B.O.D & advisory committee.
The SP is being supported above the bought deal price.
The instution who did the deal, also has options. They certainly would like to see that price as a minimum.
jusy saying.